Potential of PSMA for breast cancer in nuclear medicine: digital quantitative immunohistochemical analysis and implications for a theranostic approach.
Humans
Female
Male
Breast Neoplasms
/ pathology
Glutamate Carboxypeptidase II
/ metabolism
Retrospective Studies
Middle Aged
Antigens, Surface
/ metabolism
Immunohistochemistry
Aged
Adult
Theranostic Nanomedicine
/ methods
Nuclear Medicine
/ methods
Biomarkers, Tumor
/ metabolism
Aged, 80 and over
Precision Medicine
/ methods
Breast cancer
Human FOLH1 protein
Nuclear medicine
PSMA
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
29 Oct 2024
29 Oct 2024
Historique:
received:
04
03
2024
accepted:
16
10
2024
medline:
30
10
2024
pubmed:
30
10
2024
entrez:
30
10
2024
Statut:
epublish
Résumé
Further research is still needed to fully understand the potential of prostate-specific membrane antigen (PSMA) in breast cancer (BC) and to develop and optimize targeted therapies and imaging modalities. The objective of this study was to present a comprehensive analysis of immunohistochemistry data on PSMA staining in BC and to discuss its potential value in a theranostic approach. Fifty-eight male and female patients were randomly selected from a retrospective database of patients who underwent surgery for breast cancer between January 2012 and December 2017 and for whom a specimen is available in our tumour library. Immunodetection of PSMA and CD31 was performed on serial slides. The digitized slides were reviewed and analysed by an experienced pathologist. Additionally, the corresponding TIFF images were processed to calculate the percentage of positive neovessels. Eighteen patients (31.6%) had no expression, 29 (50.9%) had PSMA neovascular expression scored as "1", and 10 (17.5%) had neovascular expression scored as "2". Digital immunohistochemistry analysis for this last specific group of patients showed a median proportion of positive neovessels equal to 5% (range: 3-19). A multivariable logistic regression demonstrated that the odds of PSMA positivity were 4.55 times higher in non-luminal tumours and decreased by a factor of 0.12 in lobular subtypes. There was no association between sex or the presence of a germline BRCA1/2 mutation and PSMA expression in tumours. Our study highlights generally low neovascular expression of PSMA in specific histopathological subtypes of breast cancer, which will likely hamper the development of an adequate theranostic strategy. The procedure has been retrospectively registered to the French National Institute for Health Data (N° F20220615153900).
Sections du résumé
BACKGROUND
BACKGROUND
Further research is still needed to fully understand the potential of prostate-specific membrane antigen (PSMA) in breast cancer (BC) and to develop and optimize targeted therapies and imaging modalities. The objective of this study was to present a comprehensive analysis of immunohistochemistry data on PSMA staining in BC and to discuss its potential value in a theranostic approach.
METHODS
METHODS
Fifty-eight male and female patients were randomly selected from a retrospective database of patients who underwent surgery for breast cancer between January 2012 and December 2017 and for whom a specimen is available in our tumour library. Immunodetection of PSMA and CD31 was performed on serial slides. The digitized slides were reviewed and analysed by an experienced pathologist. Additionally, the corresponding TIFF images were processed to calculate the percentage of positive neovessels.
RESULTS
RESULTS
Eighteen patients (31.6%) had no expression, 29 (50.9%) had PSMA neovascular expression scored as "1", and 10 (17.5%) had neovascular expression scored as "2". Digital immunohistochemistry analysis for this last specific group of patients showed a median proportion of positive neovessels equal to 5% (range: 3-19). A multivariable logistic regression demonstrated that the odds of PSMA positivity were 4.55 times higher in non-luminal tumours and decreased by a factor of 0.12 in lobular subtypes. There was no association between sex or the presence of a germline BRCA1/2 mutation and PSMA expression in tumours.
CONCLUSIONS
CONCLUSIONS
Our study highlights generally low neovascular expression of PSMA in specific histopathological subtypes of breast cancer, which will likely hamper the development of an adequate theranostic strategy.
TRIAL REGISTRATION
BACKGROUND
The procedure has been retrospectively registered to the French National Institute for Health Data (N° F20220615153900).
Identifiants
pubmed: 39472809
doi: 10.1186/s12885-024-13065-0
pii: 10.1186/s12885-024-13065-0
doi:
Substances chimiques
FOLH1 protein, human
EC 3.4.17.21
Glutamate Carboxypeptidase II
EC 3.4.17.21
Antigens, Surface
0
Biomarkers, Tumor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1328Subventions
Organisme : La Ligue Contre le Cancer de Normandie.
ID : Not applicable
Informations de copyright
© 2024. The Author(s).
Références
Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate Cancer. N Engl J Med. 2021;385(12):1091–103.
doi: 10.1056/NEJMoa2107322
pubmed: 34161051
pmcid: 8446332
Uijen MJM, Derks YHW, Merkx RIJ, Schilham MGM, Roosen J, Privé BM, et al. PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports. Eur J Nucl Med Mol Imaging. 2021;48(13):4350–68.
doi: 10.1007/s00259-021-05433-w
pubmed: 34120192
pmcid: 8566635
Aide N, Poulain L, Elie N, Briand M, Giffard F, Blanc-Fournier C, et al. A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers. EJNMMI Res. 2021;11(1):11.
doi: 10.1186/s13550-021-00756-z
pubmed: 33559764
pmcid: 7873152
Balma M, Liberini V, Racca M, Laudicella R, Bauckneht M, Buschiazzo A, et al. Non-conventional and investigational PET radiotracers for breast Cancer: a systematic review. Front Med. 2022;9:881551.
doi: 10.3389/fmed.2022.881551
Morgenroth A, Tinkir E, Vogg ATJ, Sankaranarayanan RA, Baazaoui F, Mottaghy FM. Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer. Breast Cancer Res BCR. 2019;21(1):116.
doi: 10.1186/s13058-019-1205-1
pubmed: 31640747
Tolkach Y, Gevensleben H, Bundschuh R, Koyun A, Huber D, Kehrer C, et al. Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy. Breast Cancer Res Treat. 2018;169(3):447–55.
doi: 10.1007/s10549-018-4717-y
pubmed: 29455299
Sathekge M, Lengana T, Modiselle M, Vorster M, Zeevaart J, Maes A, et al. (68)Ga-PSMA-HBED-CC PET imaging in breast carcinoma patients. Eur J Nucl Med Mol Imaging. 2017;44(4):689–94.
doi: 10.1007/s00259-016-3563-6
pubmed: 27822700
Medina-Ornelas S, García-Perez F, Estrada-Lobato E, Ochoa-Carrillo F. (68)Ga-PSMA PET/CT in the evaluation of locally advanced and metastatic breast cancer, a single center experience. Am J Nucl Med Mol Imaging. 2020;10(3):135–42.
pubmed: 32704404
pmcid: 7364382
Orevi M, Ben-Haim S, Abourbeh G, Chicheportiche A, Mishani E, Yutkin V, et al. False positive findings of [(18)F]PSMA-1007 PET/CT in patients after radical prostatectomy with undetectable serum PSA levels. Front Surg. 2022;9:943760.
doi: 10.3389/fsurg.2022.943760
pubmed: 35813044
pmcid: 9263625
Rizzo A, Dall’Armellina S, Pizzuto DA, Perotti G, Zagaria L, Lanni V et al. PSMA Radioligand Uptake as a biomarker of Neoangiogenesis in Solid tumours: diagnostic or theragnostic factor? Cancers. 2022;14(16).
Heesch A, Ortmanns L, Maurer J, Stickeler E, Sahnoun SEM, Mottaghy FM et al. The potential of PSMA as a vascular target in TNBC. Cells. 2023;12(4).
Ayoub NM, Jaradat SK, Al-Shami KM, Alkhalifa AE. Targeting angiogenesis in breast Cancer: current evidence and future perspectives of Novel anti-angiogenic approaches. Front Pharmacol. 2022;13:838133.
doi: 10.3389/fphar.2022.838133
pubmed: 35281942
pmcid: 8913593